Neumora Therapeutics (NMRA) vs Tenaya Therapeutics (TNYA)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.
Summary
Tenaya Therapeutics (TNYA) has outperformed Neumora Therapeutics (NMRA) over the past year, losing 76.7% versus a loss of 85.7%. Tenaya Therapeutics is the larger company by market cap ($65.3 million vs $63.0 million), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | NMRA | TNYA |
|---|---|---|
| Share price | $0.3339 | $0.2866 |
| Market cap | $63.01M | $65.32M |
| 1-day change | -3.78% | -3.99% |
| YTD return | -81.35% | -59.75% |
| 1-year return | -85.67% | -76.70% |
| 5-year return | — | -98.50% |
| EPS (TTM) | $-1.06 | $-0.48 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Net income (latest FY) | $-236.93M | $-90.60M |
| 52-week high | $3.65 | $1.46 |
| 52-week low | $0.301 | $0.28 |
| Distance from 52-week high | -90.85% | -80.37% |
| Analyst consensus | buy | none |
| Avg. price target upside | +1696.95% | +1016.54% |
| Average volume | 1.69M | 2.96M |
| Shares outstanding | 188.69M | 227.93M |
| Employees | 63 | 70 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Biotechnology: Biological Products (No Diagnostic Substances) |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
About Neumora Therapeutics
NMRA stock →Neumora Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in developing therapeutic treatments for brain diseases, neuropsychiatric disorders, and neurodegenerative diseases in the United States. The company develops navacaprant (NMRA-140), a novel once-daily oral kappa opioid receptor antagonist, which is in phase 3 clinical trials for the treatment of major depressive disorder.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 63 employees
About Tenaya Therapeutics
TNYA stock →Tenaya Therapeutics, Inc., a clinical-stage biotechnology company, discovers, develops, and delivers therapies for heart disease in the United States. Its lead product candidate includes TN-201, a gene therapy for myosin binding protein C3-associated hypertrophic cardiomyopathy that is in Phase 1b/2 clinical trial; TN-401, a gene therapy for plakophilin 2-associated arrhythmogenic right ventricular cardiomyopathy, which is in Phase 1b/2 clinical trial; and TN-301, a small molecule histone deacetylase-6 for heart failure with preserved ejection fraction that is in phase 1 clinical trial.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 70 employees
NMRA vs TNYA FAQ
Which is bigger, Neumora Therapeutics or Tenaya Therapeutics?
Tenaya Therapeutics (TNYA) is larger, with a market capitalization of $65.32M compared with $63.01M for Neumora Therapeutics (NMRA).
Which stock has performed better over the past year, NMRA or TNYA?
TNYA returned -76.70% over the past 12 months, compared with -85.67% for NMRA (price return, excluding dividends). Past performance does not predict future results.
Are Neumora Therapeutics and Tenaya Therapeutics in the same industry?
Yes. Both are classified in the Biotechnology: Biological Products (No Diagnostic Substances) industry within the Health Care sector.